Skye Bioscience, Inc. · NASDAQ:SKYE
Skye Bioscience — Investor Presentation (January 2021)
20 slides from Skye Bioscience's investor presentation, January 2021
Slide 1: Emerald Bioscience: Engineering cannabinoids' pharmaceutical potential
Emerald Bioscience Engineering cannabinoids’ pharmaceutical potential Unlocking the potential of cannabinoids January 2021 OTCQB: EMBI OTC : SKYE www.skyebioscience.com
Slide 2: Disclaimer
Disclaimer Legal Disclaimer This presentation contains “forward-looking statements”, including statements regarding Emerald Bioscience, Inc. and its subsidiaries, within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All the statements in this pr
Slide 3: Skye Overview
Skye Overview NOVEL TECHNOLOGY Bioengineered, synthetic cannabinoid derivatives designed to significantly enhance therapeutic benefits COMMERCIAL POTENTIAL $6.6B+ market opportunity for lead indication, glaucoma INTELLECTUAL PROPERTY Broad “composition of matter” patent protection EXPERIENCED TEAM O
Slide 4: Glaucoma is the Leading Cause of Irreversible Blindness
Glaucoma is the Leading Cause of Irreversible Blindness Normal Vision Early Glaucoma Advanced Glaucoma Glaucoma is a disease that leads to the progressive damage of retinal ganglion cells, which make up the optic nerve, and without intervention will gradually lead to irreversible blindness C o r p o
Slide 5: Large & Growing Patient Population
Large & Growing Patient Population CURRENT GLAUCOMA PATIENTS 2040 PREDICTED GLAUCOMA PATIENTS ~78M ~100M No current cure, treatments focus on slowing disease progression C o r p o r a t e P r e s e n t a t i o n I 2 0 2 1 P.5
Slide 6: How Does Glaucoma Cause Blindness?
How Does Glaucoma Cause Blindness? A common trait of glaucoma involves increased pressure in the eye: “intraocular pressure” (IOP) Normal Eye Glaucoma Optic nerve Optic nerve Optic nerve Production/drainage of Drainage canal becomes Increased pressure aqueous humor (fluid) blocked, fluid builds up a
Slide 7: Current Therapies Leave Notable Unmet Needs
Current Therapies Leave Notable Unmet Needs IOP Class of Medication Generic Name Mechanism of Action Reduction • Glaucoma drugs represent $6.6B global Prostaglandins Analogs Latanoprost 30-35% market, growing Outflow with aging population (CAGR 6.6%) and expec β-Adrenergic Blockers Timolol 20-25% Pr
Slide 8: Relevance of THC to Glaucoma
Relevance of THC to Glaucoma • Cannabinoid receptors throughout the body play important role in managing many vital body functions • Eye is rich with cannabinoid receptors, specifically in tissues involved in managing fluid production and drainage as well as cells responsible for vision • THC and th
Slide 9: Multiple Independent Studies Have Demonstrated THC's Ability to Lower IOP
Multiple Independent Studies Have Demonstrated THC’s Ability to Lower IOP C o r p o r a t e P r e s e n t a t i o n I 2 0 2 1 P.9
Slide 10: Challenges to THC as an Effective Treatment of Glaucoma
Challenges to THC as an Effective Treatment of Glaucoma Systemic delivery • Requires relatively high dose to achieve therapeutic effect in the eye • Variable pharmacokinetics and pharmacodynamics • Poor oral bioavailability when ingested (<10% due to poor absorption) • Limited duration of effect whe
Slide 11: SKYE's Approach Unlocks Therapeutic Value of THC
SKYE’s Approach Unlocks Therapeutic Value of THC • Rational drug design and bioengineering used to develop a synthetic prodrug of THC, called THCVHS • Addition of Valine-Hemi-Succinate amide ester (VHS) to the THC molecule enhances aqueous solubility and surface polarity characteristics, enabling si
Slide 12: THCVHS Lowers IOP Better than both Market Leaders
THCVHS Lowers IOP Better than both Market Leaders • In a rabbit model, THCVHS achieves superior decline in IOP versus latanoprost and timolol • Superior duration of pharmacologic activity • Potential for once-daily dosing • Additional head-to-head studies against and in combination with Rhopressa (n
Slide 13: THC Multi-factorial Mechanism of Action in the Eye
THC-Multi-factorial Mechanism of Action in the Eye • In a 3D model of human trabecular meshwork tissues (responsible for fluid drainage), THC significantly lowered pressure and increased drainage in both healthy and disease-simulated tissue • THC treatment significantly reduced markers associated wi
Slide 14: Not all Glaucoma Patients Have Elevated IOP
Not all Glaucoma Patients Have Elevated IOP • Large proportion of glaucoma patients present with normal IOP, but still suffer % of glaucoma patients with normal IOP progressive damage to optic nerve cells and vision loss • Not clear what causes neurodegeneration of China Japan 78-92% optic nerve in
Slide 15: Positioned for Value Creation
Positioned for Value Creation Q3-21 Q1-21 Q1-22 First-in-human trial Preclinical optic in Australia nerve injury study Clinical trial to validate data neuroprotection 2021 2022 First human trial will be fast, low cost, and IND-enabling GLP repeat-dose include assessment of toxicity data intraocular
Slide 16: SKYE in a Unique Competitive Position
SKYE in a Unique Competitive Position SKYE has shown greater IOP lowering than market-leading glaucoma therapeutics Potential neuroprotection capabilities would be a game changer Key preclinical data (IOP/neuroprotection) by Q2-2021 First clinical trial: fast; low-cost; will include assessment of in
Slide 17: Capitalization
Capitalization Common Shares Outstanding 288.1 M Options & Warrants 179.6 M Convertible Debt Shares (As Converted Basis) 5 .1 M 2 Fully Diluted 472.8 M Market Cap $ 10.5 M 1 Base of Operations San Diego, CA * 1 Based on 21/01/05 OTCQB closing price of $.042 * 2 Based on $2,014,500 of outstanding pri
Slide 18: Management: Focused Path to Data Outcomes
Management: Focused Path to Data Outcomes PUNIT DHILLON – Chief Executive Officer, Chair RODERIC COLE, PhD – Head of Research & • Co-founded and led OncoSec Medical, a cancer Development immunotherapy company, through early • Principal, Blue Collar Scientific: preclinical drug development and a part
Slide 19: Scientific Advisors & Board Directors Offer Expert Guidance
Scientific Advisors & Board Directors Offer Expert Guidance Eminent experts in ophthalmology, research, and development applying their knowledge to SKYE’s mission ROBERT RITCH, MD JEFFERY GOLDBERG, MD, PhD LOUIS PASQUALE, MD EDUARDO MUNOZ, MD, PhD Professor of Ophthalmology, Mt. Sinai Professor of O
Slide 20: To Learn More Please Contact
TO L EAR N MOR E P L EAS E CON TAC T : Punit Dhillon Chief Executive Officer [E] [email protected] [P] 1.949.336.3437 Karam Takhar Vice President, OTCQB: SKYE Corporate Development & Investor Relations WWW.SKYEBIOSCIENCE.COM [E] [email protected] [P] 1.949.336.3437
Skye Bioscience — Investor Presentation (January 2021) on 6ix